Baker McKenzie Advised Sino Biopharmaceutical On Its Partnership With Boehringer Ingelheim
Baker McKenzie has Advised Sino Biopharmaceutical Limited (Sino Biopharm) on its strategic collaboration with Boehringer
Baker McKenzie Advised Sino Biopharmaceutical On Its Partnership With Boehringer Ingelheim
Baker McKenzie has Advised Sino Biopharmaceutical Limited (Sino Biopharm) on its strategic collaboration with Boehringer Ingelheim, aimed at introducing Boehringer Ingelheim’s cutting-edge cancer therapies to the mainland China market.
As per the partnership agreement, both firms will collaborate on the development and marketing of several advanced oncology treatments from Boehringer's pipeline, including brigimadlin, zongertinib, and DLL3/CD3 T-cell engager, which are in advanced stages of clinical development. For further information on the agreement, please consult the company's official announcement.
By combining forces, Sino Biopharm and Boehringer Ingelheim aim to address the unmet medical needs of cancer patients in mainland China and provide them with access to potentially life-saving treatments.
The deal was brokered by a cross-office, cross-practice team led by Julia Schieber, a partner specializing in intellectual property (IP) at Baker McKenzie, and Yilan Yang, senior counsel at FenXun, Baker McKenzie's joint operation partner in China. The team also included Derek Poon, a partner specializing in mergers and acquisitions/private equity (M&A/PE), along with other legal professionals from Baker McKenzie's offices in Hong Kong, Shanghai, Beijing, Zurich, Dubai, and London.
Commenting on the partnership, Julia expressed her satisfaction said, “We are very pleased to have assisted Sino Biopharm on this strategic transaction, which marks a milestone in the company’s journey to improve China’s access to innovative, international drugs. This transaction demonstrates our unrivalled ability to assist companies across multi-faceted issues in complex cross-border transaction and our deep knowledge and experience in the healthcare and life sciences sectors.”
Derek added: “As Sino Biopharm continues with its pursuit of “In China for Global” and “In Global for Global” strategy, we look forward to continuing to support the company and help them connect with business partners and opportunities worldwide, something which Baker McKenzie has been doing for all our clients for the last 75 years.”